The contribution of DNA mismatch repair gene defects to the burden of gynecological cancer
A.C. Drake,
H. Campbell, M.E.M. Porteous,
M.G. Dunlop,
Corresponding Author
A.C. Drake
University of Edinburgh, Edinburgh, United Kingdom
Address correspondence and reprint requests to: Alasdair C Drake, Department of Gynaecological Oncology, St James's Hospital, Leeds LS9 7LP, United Kingdom. E-mail: [email protected].Search for more papers by this authorM.E.M. Porteous
University of Edinburgh, Edinburgh, United Kingdom
Search for more papers by this authorA.C. Drake,
H. Campbell, M.E.M. Porteous,
M.G. Dunlop,
Corresponding Author
A.C. Drake
University of Edinburgh, Edinburgh, United Kingdom
Address correspondence and reprint requests to: Alasdair C Drake, Department of Gynaecological Oncology, St James's Hospital, Leeds LS9 7LP, United Kingdom. E-mail: [email protected].Search for more papers by this authorM.E.M. Porteous
University of Edinburgh, Edinburgh, United Kingdom
Search for more papers by this author
References
- 1 Cancer Registration Statistics Scotland 198695 http://www.show.scot.nhs.uk/isdcancerfacts_figures typesfacts_figures_fgenital.html. May 15, 2003.
- 2 http://www.seer.cancer.govfaststatshtmlmor_ corp.html. May 15, 2003.
- 3 Von Gruenigen VE, Karlen JR. Carcinoma of the endometrium. Am Fam Physician 1995; 51: 1531 – 6,1541 – 2.
- 4
Terry P,
Baron JA,
Weiderpass E,
Yuen J,
Lichtenstein P,
Nyren O.
Lifestyle and endometrial cancer risk: a cohort study from the Swedish Twin Registry.
Int J Cancer
1999; 82:
38
–
42.
10.1002/(SICI)1097-0215(19990702)82:1<38::AID-IJC8>3.0.CO;2-Q CAS PubMed Web of Science® Google Scholar
- 5 Parazzini F, La Vecchia C, Negri E, Fedele L, Balotta F. Reproductive factors and risk of endometrial cancer. Am J Obstet Gynecol 1991; 164: 522 – 7.
- 6 Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, Escudero-de los Rios P, Salmeron-Castro J, Hernandez-Avila M. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico. Cancer Res 1999; 59: 3658 – 62.
- 7 Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349: 458 – 61.
- 8 Weiderpass E, Adami HO, Baron JA et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 1131 – 7.
- 9 Niwa K, Imai A, Hashimoto M et al. A case-control study of uterine endometrial cancer of pre- and post-menopausal women. Oncol Rep 2000; 7: 89 – 93.
- 10 http://www_Seer.Cancer.govfaststatshtmlinc_ovary.html. May 15, 2003.
- 11 Friebe Z, Bembnista M, Nowakowski B. [Evaluation of risk factors for endometrial adenocarcinoma in women with diabetes, hypertension and obesity hospitalized for pathologic uterine hemorrhage around the age of postmenopause]. Ginekol Pol 1997; 68: 361 – 9.
- 12 Bristow RE, Karlan BY. The risk of ovarian cancer after treatment for infertility. Curr Opin Obstet Gynecol 1996; 8: 32 – 7.
- 13 Mant JW, Vessey MP. Ovarian and endometrial cancers. Cancer Surv 1994; 20: 287 – 307.
- 14 Dunlop MG, Farrington SM, Nicholl I et al. Population carrier frequency of hMSH2 and hMLH1 mutations. Br J Cancer 2000; 83: 1643 – 5.
- 15 Warthin AS. Heredity with reference to carcinoma. Arch Intern Med 1913; 12: 546 – 55.
- 16 Dunlop MG, Farrington SM, Carothers AD et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997; 6: 105 – 10.
- 17 Lin KM, Shashidharan M, Thorson AG et al. Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer. J Gastrointest Surg 1998; 2: 67 – 71.
- 18 Vasen HF, Wijnen JT, Menko FH et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 110: 1020 – 7.
- 19
Aarnio M,
Sankila R,
Pukkala E et al.
Cancer risk in mutation carriers of DNA-mismatch-repair genes.
Int J Cancer
1999; 81:
214
–
8.
10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L CAS PubMed Web of Science® Google Scholar
- 20 Watson P, Vasen HF, Mecklin JP, Jarvinen H, Lynch HT. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994; 96: 516 – 20.
- 21 Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34: 424 – 5.
- 22 Rodriguez-Bigas MA, Boland CR, Hamilton SR et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997; 89: 1758– 62.
- 23 Syngal S, Fox EA, Eng C, Kolodner RD, Garber JE. Sensitivity and specificity of clinical criteria for hereditary non- polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 2000; 37: 641 – 5.
- 24 Gu L, Cline-Brown B, Zhang F, Qiu L, Li GM. Mismatch repair deficiency in hematological malignancies with microsatellite instability. Oncogene 2002; 21: 5758 – 64.
- 25 Bocker T, Ruschoff J, Fishel R. Molecular diagnostics of cancer predisposition: hereditary non- polyposis colorectal carcinoma and mismatch repair defects. Biochim Biophys Acta 1999; 1423: 1 – 10.
- 26 Kolodner RD, Marsischky GT. Eukaryotic DNA mismatch repair. Curr Opin Genet Dev 1999; 9: 89 – 96.
- 27 Fishel R. Mismatch repair, molecular switches, and signal transduction. Genes Dev 1998; 12: 2096 – 101.
- 28 International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer. http://www.nfdht.nl/ May 15, 2003.
- 29 Heinen CD, Wilson T, Mazurek A, Berardini M, Butz C, Fishel R. HNPCC mutations in hMSH2 result in reduced hMSH2-hMSH6 molecular switch functions. Cancer Cell 2002; 1: 469 – 78.
- 30 Kariola R, Raevaara TE, Lonnqvist KE, Nystrom-Lahti M. Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome. Hum Mol Genet 2002; 11: 1303 – 10.
- 31 Ichikawa Y, Lemon SJ, Wang S et al. Microsatellite instability and expression of MLH1 and MSH2 in normal and malignant endometrial and ovarian epithelium in hereditary nonpolyposis colorectal cancer family members. Cancer Genet Cytogenet 1999; 112: 2 – 8.
- 32
Arzimanoglou II,
Gilbert F,
Barber HR.
Microsatellite instability in human solid tumors.
Cancer
1998; 82:
1808
–
20.
10.1002/(SICI)1097-0142(19980515)82:10<1808::AID-CNCR2>3.0.CO;2-J CAS PubMed Web of Science® Google Scholar
- 33 Eshleman JR, Markowitz SD. Microsatellite instability in inherited and sporadic neoplasms. Curr Opin Oncol 1995; 7: 83 – 9.
- 34 Kane MF, Loda M, Gaida GM et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997; 57: 808 – 11.
- 35
Yanagisawa Y,
Akiyama Y,
Iida S et al.
Methylation of the hMLH1 promoter in familial gastric cancer with microsatellite instability.
Int J Cancer
2000; 85:
50
–
3.
10.1002/(SICI)1097-0215(20000101)85:1<50::AID-IJC9>3.0.CO;2-E CAS PubMed Web of Science® Google Scholar
- 36 Fleisher AS, Esteller M, Wang S et al. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 1999; 59: 1090 – 5.
- 37
Gras E,
Catasus L,
Arguelles R et al.
Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors.
Cancer
2001; 92:
2829
–
36.
10.1002/1097-0142(20011201)92:11<2829::AID-CNCR10094>3.0.CO;2-3 CAS PubMed Web of Science® Google Scholar
- 38 De Leeuw WJ, Dierssen J, Vasen HF et al. Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients. J Pathol 2000; 192: 328 – 35.
- 39 Kondo E, Furukawa T, Yoshinaga K et al. Not hMSH2 but hMLH1 is frequently silenced by hypermethylation in endometrial cancer but rarely silenced in pancreatic cancer with microsatellite instability. Int J Oncol 2000; 17: 535 – 41.
- 40 Salvesen HB, MacDonald N, Ryan A et al. Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res 2000; 6: 3607 – 13.
- 41 Simpkins SB, Bocker T, Swisher EM et al. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet 1999; 8: 661 – 6.
- 42 Gurin CC, Federici MG, Kang L, Boyd J. Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Res 1999; 59: 462 – 6.
- 43 Esteller M, Catasus L, Matias-Guiu X Et Al. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 1999; 155: 1767 – 72.
- 44 Deleted in proof.
- 45 Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998; 17: 2413 – 7.
- 46 Schoen RE, Weissfeld JL, Kuller LH. Are women with breast, endometrial, or ovarian cancer at increased risk for colorectal cancer? Am J Gastroenterol 1994; 89: 835 – 42.
- 47 Gruber SB, Thompson WD. A population-based study of endometrial cancer and familial risk in younger women. Cancer Steroid Hormone Study Group. Cancer Epidemiol Biomarkers Prev 1996; 5: 411 – 7.
- 48 Sumoi R, Hakala-Ala-Pietila T, Leminen A, Mecklin JP, Lehtovirta P. Hereditary aspects of endometrial adenocarcinoma. Int J Cancer 1995; 62: 132 – 7.
- 49
Lynch HT,
Krush AJ.
Cancer family ‘G’ revisited: 1895–1970.
Cancer
1971; 27:
1505
–
11.
10.1002/1097-0142(197106)27:6<1505::AID-CNCR2820270635>3.0.CO;2-L CAS PubMed Web of Science® Google Scholar
- 50
Olson JE,
Sellers TA,
Anderson KE,
Folsom AR.
Does a family history of cancer increase the risk for postmenopausal endometrial carcinoma? A prospective cohort study and a nested case- control family study of older women.
Cancer
1999; 85:
2444
–
9.
10.1002/(SICI)1097-0142(19990601)85:11<2444::AID-CNCR20>3.0.CO;2-M CAS PubMed Web of Science® Google Scholar
- 51 Mecklin JP, Jarvinen HJ, Peltokallio P. Cancer family syndrome. Genetic analysis of 22 Finnish kindreds. Gastroenterology 1986; 90: 328 – 33.
- 52
Mecklin JP,
Jarvinen HJ.
Tumor spectrum in cancer family syndrome (hereditary nonpolyposis colorectal cancer).
Cancer
1991; 68:
1109
–
12.
10.1002/1097-0142(19910901)68:5<1109::AID-CNCR2820680535>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- 53
Hakala T,
Mecklin JP,
Forss M,
Jarvinen H,
Lehtovirta P.
Endometrial carcinoma in the cancer family syndrome.
Cancer
1991; 68:
1656
–
9.
10.1002/1097-0142(19911001)68:7<1656::AID-CNCR2820680732>3.0.CO;2-7 CAS PubMed Web of Science® Google Scholar
- 54 Vasen HF, Offerhaus GJ, Den Hartog Jager FC et al. The tumour spectrum in hereditary non-polyposis colorectal cancer. a study of 24 kindreds in the Netherlands. Int J Cancer 1990; 46: 31 – 4.
- 55 Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64: 430 – 3.
- 56 Vasen HF, Watson P, Mecklin JP et al. The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Res 1994; 14: 1675 – 8.
- 57 Pal T, Flanders T, , MM-L, MacMillan A et al. Genetic implications of double primary cancers of the colorectum and endometrium. J Med Genet 1998; 35: 978 – 84.
- 58 Millar AL, Pal T, Madlensky L et al. Mismatch repair gene defects contribute to the genetic basis of double primary cancers of the colorectum and endometrium. Hum Mol Genet 1999; 8: 823 – 9.
- 59
Cederquist K,
Golovleva I,
Emanuelsson M,
Stenling R,
Gronberg H.
A population based cohort study of patients with multiple colon and endometrial cancer: correlation of microsatellite instability (MSI) status, age at diagnosis and cancer risk.
Int J Cancer
2001; 91:
486
–
91.
10.1002/1097-0215(200002)9999:9999<::AID-IJC1093>3.0.CO;2-P CAS PubMed Web of Science® Google Scholar
- 60 Duggan BD, Felix JC, Muderspach LI, Tourgeman D, Zheng J, Shibata D. Microsatellite instability in sporadic endometrial carcinoma. J Natl Cancer Inst 1994; 86: 1216 – 21.
- 61
Kowalski LD,
Mutch DG,
Herzog TJ,
Rader JS,
Goodfellow PJ.
Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers.
Genes Chromosomes Cancer
1997; 18:
219
–
27.
10.1002/(SICI)1098-2264(199703)18:3<219::AID-GCC8>3.0.CO;2-4 CAS PubMed Web of Science® Google Scholar
- 62 Nagase S, Sato S, Tezuka F, Wada Y, Yajima A, Horii A. Deletion mapping on chromosome 10q25-q26 in human endometrial cancer. Br J Cancer 1996; 74: 1979 – 83.
- 63 Peltomaki P, Lothe RA, Aaltonen LA et al. Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res 1993; 53: 5853 – 5.
- 64 Sakamoto T, Murase T, Urushibata H et al. Microsatellite instability and somatic mutations in endometrial carcinomas. Gynecol Oncol 1998; 71: 53 – 8.
- 65 Ohwada M, Suzuki M, Kashiwagi H, Konishi F, Sato I. DNA replication error in endometrial carcinoma and complex atypical endometrial hyperplasia. Cancer Genet Cytogenet 1999; 114: 130 – 5.
- 66 Tashiro H, Blazes MS, Wu R et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997; 57: 3935 – 40.
- 67 Tashiro H, Lax SF, Gaudin PB, Isacson C, Cho KR, Hedrick L. Microsatellite instability is uncommon in uterine serous carcinoma. Am J Pathol 1997; 150: 75 – 9.
- 68 Swisher EM, Mutch DG, Herzog TJ et al. Analysis of MSH3 in endometrial cancers with defective DNA mismatch repair. J Soc Gynecol Invest 1998; 5: 210 – 6.
- 69 Caduff RF, Johnston CM, Svoboda-Newman SM, Poy EL, Merajver SD, Frank TS. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 1996; 148: 1671 – 8.
- 70 Lim PC, Tester D, Cliby W et al. Absence of mutations in DNA mismatch repair genes in sporadic endometrial tumors with microsatellite instability. Clin Cancer Res 1996; 2: 1907 – 11.
- 71 Ercoli A, Ferrandina G, Raspaglio G et al. hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer. Br J Cancer 1999; 80: 1665 – 71.
- 72 Sirchia SM, Pariani S, Rossella F et al. Cytogenetic abnormalities and microsatellite instability in endometrial adenocarcinoma. Cancer Genet Cytogenet 1997; 94: 113 – 9.
- 73 Jovanovic AS, Boynton KA, Mutter GL. Uteri of women with endometrial carcinoma contain a histopathological spectrum of monoclonal putative precancers, some with microsatellite instability. Cancer Res 1996; 56: 1917 – 21.
- 74 Katabuchi H, Van Rees B, Lambers AR et al. Mutations in DNA mismatch repair genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas. Cancer Res 1995; 55: 5556 – 60.
- 75 Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993; 53: 5100 – 3.
- 76 Kobayashi K, Matsushima M, Koi S et al. Mutational analysis of mismatch repair genes, hMLH1 and hMSH2, in sporadic endometrial carcinomas with microsatellite instability. Jpn J Cancer Res 1996; 87: 141 – 5.
- 77
Helland A,
Borresen-Dale AL,
Peltomaki P et al.
Microsatellite instability in cervical and endometrial carcinomas.
Int J Cancer
1997; 70:
499
–
501.
10.1002/(SICI)1097-0215(19970304)70:5<499::AID-IJC1>3.0.CO;2-T CAS PubMed Web of Science® Google Scholar
- 78 Burks RT, Kessis TD, Cho KR, Hedrick L. Microsatellite instability in endometrial carcinoma. Oncogene 1994; 9: 1163 – 6.
- 79 MacDonald ND, Salvesen HB, Ryan A, Iversen OE, Akslen LA, Jacobs IJ. Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. Cancer Res 2000; 60: 1750 – 2.
- 80 Maxwell GL, Risinger JI, Alvarez AA, Barrett JC, Berchuck A. Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. Obstet Gynecol 2001; 97: 417 – 22.
- 81 Catasus L, Machin P, Matias-Guiu X, Prat J. Microsatellite instability in endometrial carcinomas. clinicopathologic correlations in a series of 42 cases. Hum Pathol 1998; 29: 1160 – 4.
- 82 Schweizer P, Moisio AL, Kuismanen SA et al. Lack of MSH2 and MSH6 characterizes endometrial but not colon carcinomas in hereditary nonpolyposis colorectal cancer. Cancer Res 2001; 61: 2813 – 5.
- 83 Berends MJ, Hollema H, Wu Y et al. MLH1 and MSH2 protein expression as a pre-screening marker in hereditary and non-hereditary endometrial hyperplasia and cancer. Int J Cancer 2001; 92: 398 – 403.
- 84 Chiaravalli AM, Furlan D, Facco C et al. Immunohistochemical pattern of hMSH2/hMLH1 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences. Virchows Arch 2001; 438: 39 – 48.
- 85 Ichikawa Y, Tsunoda H, Takano K, Oki A, Yoshikawa H. Microsatellite instability and immunohistochemical analysis of MLH1 and MSH2 in normal endometrium, endometrial hyperplasia and endometrial cancer from a hereditary nonpolyposis colorectal cancer patient. Jpn J Clin Oncol 2002; 32: 110 – 2.
- 86 Stefansson I, Akslen LA, MacDonald N et al. Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. Clin Cancer Res 2002; 8: 138 – 43.
- 87 Peiro G, Diebold J, Lohse P, Ruebsamen H, Baretton GB, Lohrs U. Microsatellite instability, loss of heterozygosity, and loss of hMLH1 and hMSH2 protein expression in endometrial carcinoma. Hum Pathol 2002; 33: 347 – 54.
- 88
Maruyama A,
Miyamoto S,
Saito T,
Kondo H,
Baba H,
Tsukamoto N.
Clinicopathologic and familial characteristics of endometrial carcinoma with multiple primary carcinomas in relation to the loss of protein expression of MSH2 and MLH1.
Cancer
2001; 91:
2056
–
64.
10.1002/1097-0142(20010601)91:11<2056::AID-CNCR1232>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- 89 Staebler A, Lax SF, Ellenson LH. Altered expression of hMLH1 and hMSH2 protein in endometrial carcinomas with microsatellite instability. Hum Pathol 2000; 31: 354 – 8.
- 90 Park YRA, Halling KC, Burgart LJ, Thibodeau SN, Halling AC. Altered expression of hMLH1 and hMSH2 and microsatellite instability in young patients with endometrial carcinoma. American Association for Cancer Reasearch; 1999;40:1369.
- 91 Planck M, Rambech E, Moslein G, Muller W, Olsson H, Nilbert M. High frequency of microsatellite instability and loss of mismatch-repair protein expression in patients with double primary tumors of the endometrium and colorectum. Cancer 2002; 94: 2502 – 10.
- 92 Baldinu P, Cossu A, Manca A et al. Microsatellite instability and mutation analysis of candidate genes in unselected sardinian patients with endometrial carcinoma. Cancer 2002; 94: 3157 – 68.
- 93 Charames GS, Millar AL, Pal T, Narod S, Bapat B. Do MSH6 mutations contribute to double primary cancers of the colorectum and endometrium? Hum Genet 2000; 107: 623 – 9.
- 94 Miyaki M, Konishi M, Tanaka K et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997; 17: 271 – 2.
- 95 Wijnen J, Leeuw W, Vasen H et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet 1999; 23: 142 – 4.
- 96
Planck M,
Koul A,
Fernebro E et al.
hMLH1, hMSH2 and hMSH6 mutations in hereditary non-polyposis colorectal cancer families from southern Sweden.
Int J Cancer
1999; 83:
197
–
202.
10.1002/(SICI)1097-0215(19991008)83:2<197::AID-IJC9>3.0.CO;2-X CAS PubMed Web of Science® Google Scholar
- 97
Fornasarig M,
Campagnutta E,
Talamini R et al.
Risk factors for endometrial cancer according to familial susceptibility.
Int J Cancer
1998; 77:
29
–
32.
10.1002/(SICI)1097-0215(19980703)77:1<29::AID-IJC6>3.0.CO;2-1 CAS PubMed Web of Science® Google Scholar
- 98 Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984; 64: 417 – 20.
- 99 Crissman JD, Azoury RS, Barnes AE, Schellhas HF. Endometrial carcinoma in women 40 years of age or younger. Obstet Gynecol 1981; 57: 699 – 704.
- 100 Gitsch G, Hanzal E, Jensen D, Hacker NF. Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol 1995; 85: 504 – 8.
- 101 Evans-Metcalf ER, Brooks SE, Reale FR, Baker SP. Profile of women 45 years of age and younger with endometrial cancer. Obstet Gynecol 1998; 91: 349 – 54.
- 102 Kobayashi K, Sagae S, Kudo R, Saito H, Koi S, Nakamura Y. Microsatellite instability in endometrial carcinomas. frequent replication errors in tumors of early onset and/or of poorly differentiated type. Genes Chromosomes Cancer 1995; 14: 128 – 32.
- 103 Peiro G, Diebold J, Mayr D et al. Prognostic relevance of hMLH1, hMSH2, and BAX protein expression in endometrial carcinoma. Mod Pathol 2001; 14: 777 – 83.
- 104
Watson P,
Lynch HT.
Extracolonic cancer in hereditary nonpolyposis colorectal cancer.
Cancer
1993; 71:
677
–
85.
10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-# CAS PubMed Web of Science® Google Scholar
- 105 Arzimanoglou II, Lallas T, Osborne M, Barber H, Gilbert F. Microsatellite instability differences between familial and sporadic ovarian cancers. Carcinogenesis 1996; 17: 1799– 804.
- 106 King BL, Carcangiu ML, Carter D et al. Microsatellite insta- bility in ovarian neoplasms. Br J Cancer 1995; 72: 376 – 82.
- 107 Haas CJ, Diebold J, Hirschmann A, Rohrbach H, Schmid S, Lohrs U. Microsatellite analysis in serous tumors of the ovary. Int J Gynecol Pathol 1999; 18: 158 – 62.
- 108 Suzuki M, Ohwada M, Saga Y, Saito S, Sato I. Are DNA mismatch repair deficiencies responsible for accumulation of genetic alterations in epithelial ovarian cancers? Cancer Genet Cytogenet 2001; 124: 152 – 8.
- 109 Stratton JF, Thompson D, Bobrow L et al. The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study. Am J Hum Genet 1999; 65: 1725– 32.
- 110 Kolodner RD, Hall NR, Lipford J et al. Structure of the human MSH2 locus and analysis of two Muir-Torre kindreds for msh2 mutations. Genomics 1994; 24: 516 – 26.
- 111
Anderson DE.
An inherited form of large bowel cancer: Muir's syndrome.
Cancer
1980; 45:
1103
–
7.
10.1002/1097-0142(19800315)45:5+<1103::AID-CNCR2820451313>3.0.CO;2-D CAS PubMed Web of Science® Google Scholar
- 112 Jacobs DM, Sandles LG, Leboit PE. Sebaceous carcinoma arising from Bowen's disease of the vulva. Arch Dermatol 1986; 122: 1191 – 3.
- 113 Park JG, Vasen HF, Park KJ et al. Suspected hereditary nonpolyposis colorectal cancer. International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG- HNPCC) criteria and results of genetic diagnosis. Dis Colon Rectum 1999; 42: 710 – 5. discussion 715 – 6.
- 114 Cancer Genetics Services in Scotland. Guidance to support the implementation of Genetic Services for Breast, Ovarian and Colorectal Cancer Predisposition. http://www.show.scot.nhs.uk/sehd/mels/HDL2001-24/Guide.pdf/. May 15, 2003.
- 115 Burke W, Petersen G, Lynch P et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genet Studies Consortium. JAMA 1997; 277: 915 – 9.
- 116 Simmang CL, Senatore P, Lowry A et al. Practice parameters for detection of colorectal neoplasms. The Standards Committee, The American Society of Colon and Rectal Surgeons. Dis Colon Rectum 1999; 42: 1123 – 9.
- 117 Hodgson SV, Bishop DT, Dunlop MG, Evans DG, Northover JM. Suggested screening guidelines for familial colorectal cancer. J Med Screen 1995; 2: 45 – 51.
- 118 Moore J, Cowled P. Hereditary non-polyposis colorectal cancer syndrome. Aust N Z J Surg 1999; 69: 6 – 13.
- 119 Ferrazzi E, Torri V, Trio D, Zannoni E, Filiberto S, Dordoni D. Sonographic endometrial thickness: a useful test to predict atrophy in patients with postmenopausal bleeding. An Italian multicenter study. Ultrasound Obstet Gynecol 1996; 7: 315 – 21.
- 120 Smith-Bindman R, Kerlikowske K, Feldstein VA et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA 1998; 280: 1510 – 7.
- 121 Ferry J, Farnsworth A, Webster M, Wren B. The efficacy of the pipelle endometrial biopsy in detecting endometrial carcinoma. Aust N Z J Obstet Gynaecol 1993; 33: 76 – 8.
- 122 Stovall TG, Photopulos GJ, Poston WM, Ling FW, Sandles LG. Pipelle endometrial sampling in patients with known endometrial carcinoma. Obstet Gynecol 1991; 77: 954 – 6.
- 123 Dubbins PA, Subba B. Screening for gynecological malignancy. Semin Ultrasound CT MR 1999; 20: 231 – 8.
- 124 Spencer CP, Whitehead MI. Endometrial assessment re-visited. Br J Obstet Gynaecol 1999; 106: 623 – 32.
- 125 Rosenthal AN, Jacobs IJ. The role of CA 125 in screening for ovarian cancer. Int J Biol Markers 1998; 13: 216 – 20.
- 126 Bell R, Petticrew M, Luengo S, Sheldon TA. Screening for ovarian cancer: a systematic review. Health Technol Assess 1998; 2: 1 – 84.
- 127 MacDonald ND, Jacobs IJ. Is there a place for screening in ovarian cancer? Eur J Obstet Gynecol Reprod Biol 1999; 82: 155 – 7.
- 128 Menon U, Jacobs IJ. Recent developments in ovarian cancer screening. Curr Opin Obstet Gynecol 2000; 12: 39 – 42.
- 129 Boyd J, Rubin SC. Hereditary ovarian cancer. molecular genetics and clinical implications. Gynecol Oncol 1997; 64: 196 – 206.
- 130 Fry A, Busby-Earle C, Rush R, Cull A. Prophylactic oophorectomy versus screening. psychosocial outcomes in women at increased risk of ovarian cancer. Psychooncology 2001; 10: 231 – 41.
- 131 Gotlieb WH, Baruch GB, Friedman E. Prophylactic oophorectomy: clinical considerations. Semin Surg Oncol 2000; 19: 20 – 7.
- 132 Eisinger F, Alby N, Bremond A et al. Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee. Ann Oncol 1998; 9: 939 – 50.
- 133 Moller P, Evans G, Haites N et al. Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer. Dis Markers 1999; 15: 207 – 11.
- 134 Sjodahl R. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Extent, mode, and dose dependence of anticancer effects. Am J Med 2001; 110: 66S – 69S.
- 135 Gupta RA, DuBois RN. Translational studies on Cox-2 inhibitors in the prevention and treatment of colon cancer. Ann N Y Acad Sci 2000; 910: 196 – 204. discussion 204 – 6.
- 136 Kalgutkar AS, Crews BC, Rowlinson SW, Garner C, Seibert K, Marnett LJ. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science 1998; 280: 1268 – 70.
- 137 Bak AW, McKnight W, Li P et al. Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci 1998; 62: L 367 – 73.
- 138 Rodriguez-Burford C, Barnes MN, Oelschlager DK et al. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 2002; 8: 202 – 9.
- 139 Shiff SJ, Rigas B. Aspirin for cancer. Nat Med 1999; 5: 1348 – 9.
- 140 Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18: 7908 – 16.
- 141 Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996; 56: 4566 – 9.
- 142 Husain SS, Szabo IL, Tamawski AS. NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am J Gastroenterol 2002; 97: 542 – 53.
- 143 Vainio H, Morgan G. Non-steroidal anti-inflammatory drugs and chemoprevention of cancer. Ann Chir Gynaecol 2000; 89: 173 – 6.
- 144 Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents. mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252 – 66.
- 145 Xu XC. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs 2002; 13: 127 – 37.
- 146 Eisen A, Rebbeck TR, Wood WC, Weber BL. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol 2000; 18: 1980 – 95.
- 147 Rebbeck TR. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2000; 18: 100S – 3S.
- 148 Shih HA, Nathanson KL, Seal S et al. BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. Clin Cancer Res 2000; 6: 4259 – 64.
- 149 Rebbeck TR. More about. modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 2000; 92: 76.
- 150 Fong YF, Lim FK, Arulkumaran S. Prophylactic oophorectomy: a continuing controversy. Obstet Gynecol Surv 1998; 53: 493 – 9.
- 151 Chen KT, Schooley JL, Flam MS. Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome. Obstet Gynecol 1985; 66: 93S – 94S.
- 152 Brown R, Hirst GL, Gallagher WM et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 1997; 15: 45 – 52.
- 153 Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999; 18: 2335 – 41.
- 154 Holford J, Beale PJ, Boxall FE, Sharp SY, Kelland LR. Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines. Eur J Cancer 2000; 36: 1984 – 90.
- 155 Samimi G, Fink D, Varki NM et al. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy 2000;6: 1415 – 21.
- 156 Fink D, Nebel S, Aebi S et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996; 56: 4881 – 6.
- 157 Fedier A, Schwarz VA, Walt H, Carpini RD, Haller U, Fink D. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int J Cancer 2001; 93: 571 – 6.
- 158 Dosch J, Christmann M, Kaina B. Mismatch G-T binding activity and MSH2 expression is quantitatively related to sensitivity of cells to methylating agents. Carcinogenesis 1998; 19: 567 – 73.
- 159 Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000; 60: 6039 – 44.
- 160 Mello JA, Acharya S, Fishel R, Essigmann JM. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol 1996; 3: 579 – 89.
- 161 Liu L, Schwartz S, Davis BM, Gerson SL. Chemotherapy-induced O (6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer. Cancer Res 2002; 62: 3070 – 6.
- 162 Umar A, Koi M, Risinger JI et al. Correction of hypermutability, N-methyl-N′-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res 1997; 57: 3949 – 55.
